ICU Medical, Inc. (ICUI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's Q3 results show strong financial performance with improved gross margins and EPS growth. The Consumables and IV Systems segments performed well, despite challenges in the Vital Care segment. Management's cautious optimism and strategic focus on growth areas like Consumables and Systems, coupled with efforts to mitigate tariff impacts, support a positive outlook. The market cap suggests moderate volatility, leading to a predicted positive stock price movement of 2% to 8%.
Key Financial Performance
Revenue $533 million for Q3 2025, representing a total company growth of 5% on an organic basis or a decrease of 8% reported year-over-year. The reported results were impacted by the midyear creation of the Otsuka ICU Medical JV and the resulting deconsolidation of IV Solutions from the income statement.
Gross Margin Adjusted gross margin for Q3 2025 was 41%, showing a meaningful improvement year-over-year. This was influenced by three discrete items: a one-time benefit from settling the Italy medical device payback liability, the deconsolidation of the IV Solutions business, and the impact of tariffs. Excluding the 2 percentage point impact of tariffs, the gross margin would have been 43%.
Adjusted EBITDA $106 million for Q3 2025, an increase of 12% compared to $95 million in Q3 2024. This improvement was driven by increased gross margins and reduced operating expenses.
Adjusted EPS $2.03 for Q3 2025, an increase of 28% compared to $1.59 in Q3 2024. This was supported by higher gross margins and lower operating expenses.
Free Cash Flow $28 million for Q3 2025, which includes a $10 million outflow related to reducing the utilization of the accounts receivable purchase program to zero. This was a solid performance despite the impact of higher tariffs.
Consumables Business Revenue Grew 8% reported and 7% organic year-over-year in Q3 2025. Growth was driven by new global customer implementations, rapid growth in niche markets, and solid census.
IV Systems Business Revenue Grew 9% reported and 8% organic year-over-year in Q3 2025. Growth was driven by all three main product families, with LVP pumps and dedicated sets being the largest contributors.
Vital Care Segment Revenue Down 52% reported and 4% organically year-over-year in Q3 2025. The decline was due to the deconsolidation of IV Solutions revenues from the income statement.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Consumables business growth: Grew 8% reported and 7% organic in Q3, driven by new global customer implementations, rapid growth in niche markets, and solid census. Record quarter in absolute sales levels.
IV Systems business growth: Grew 9% reported and 8% organic in Q3, driven by all three main product families, including LVP pumps and dedicated sets with double-digit growth.
New product filings and innovation: Focused on enhancing patient safety and workflow efficiencies in infusion drug delivery. Includes line extensions and adjacencies combining legacy ICU and Smiths' acquisitions.
Medfusion 5000 syringe pump and CADD ambulatory pumps: Submitted 510(k)s for FDA approval. Medfusion 5000 described as groundbreaking, while CADD submission updates product iterations. Aim to connect all pump modalities to a single software solution.
Geographic demand and utilization: Broad demand and utilization environment in Q3 was attractive across almost every geography, with positive growth rates.
Competitive market share: Opportunity to win market share with a full suite of new and best-in-class products, including LVP, syringe, and ambulatory pumps.
Gross margin improvement: Adjusted gross margin for Q3 was 41%, showing meaningful improvement year-over-year and sequentially. Targeting 45% gross margin in the medium term.
Cost controls and restructuring: Implemented cost controls and deferred discretionary spending. Restructuring and integration expenses were $13 million in Q3.
Debt repayment: Repaid $273 million in principal year-to-date. Refinanced credit facility to save $2 million annually in interest expense.
Infusion-focused company strategy: Goal to build the most comprehensive and innovative infusion-focused company. Investments in R&D and capital assets to support growth.
Portfolio optimization: Exploring opportunities for portfolio optimization, such as the IV Solutions JV, to enhance revenue growth and gross margins.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariffs: The company incurred $11 million in tariffs during Q3, with an expected increase to $12-14 million in Q4. This has a direct impact on gross margins, reducing profitability by approximately 2 percentage points in Q3.
Deconsolidation of IV Solutions: The deconsolidation of IV Solutions from the income statement has reduced revenue and EBITDA, creating a headwind for financial performance.
FDA Approvals and Warning Letters: The company is awaiting FDA approvals for new infusion systems hardware and software, as well as resolution of warning letters. Delays in these processes could impact product launches and revenue growth.
Integration and Restructuring Costs: The company is incurring significant costs related to integration, restructuring, and quality system remediation, which are impacting free cash flow and overall profitability.
Interest Expense and Debt Leverage: The company has $1.3 billion in debt and is working to reduce leverage. High interest expenses and debt levels could constrain financial flexibility.
Supply Chain and Manufacturing Optimization: Ongoing efforts to consolidate production, logistics, and real estate networks are critical for achieving gross margin improvement but pose execution risks.
Economic and Market Conditions: While demand remains strong, growth rates have moderated compared to the previous year, indicating potential economic or market-related challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: For the balance of the year, the company expects mid-single-digit growth for the year, but Q4 growth rates are not expected to match Q3 levels.
Product Innovation and Approvals: The company is advancing new product filings and innovations in the Consumables business, including 510(k) submissions for Medfusion 5000 syringe pump and CADD ambulatory pumps. These products aim to enhance patient safety and workflow efficiencies. The company is also working with the FDA to gain approval for new infusion systems hardware and software.
IV Systems Business: The company expects mid-single-digit growth for the year, with a focus on refreshing the Plum 360 installed base with Plum Solo. However, Q4 growth rates are not expected to match Q3 levels due to installation schedule variability.
Gross Margin Goals: The company is progressing towards a gross margin target of 45%, excluding the impact of tariffs. Current gross margin is at 43% when adjusted for tariffs, with operational improvements expected to close the remaining gap.
Tariff Impact: Tariffs are expected to cost $25 million for the full year, with Q4 tariff expenses projected to be $12 million to $14 million.
Adjusted EBITDA and EPS Guidance: Full-year adjusted EBITDA guidance has been increased to $395 million to $405 million, and adjusted EPS guidance has been updated to $7.35 to $7.65 per share.
Leverage and Debt Management: The company expects to be 2.5x levered net debt to EBITDA by the end of 2025, with a long-term goal of 2x leverage. Recent refinancing is expected to save $2 million annually in interest expense.
Medium-Term Execution Priorities: The company aims to sustain revenue growth, gain FDA approvals for new products, complete integration activities to improve gross margins, and reduce leverage to enable capital return.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the sources of strength for Consumables?
A:The sources of strength for Consumables include marketing efforts, market share gains from customer wins in IV Solutions and Consumables, success in niche markets like oncology and dialysis, and growth in international markets, particularly Western Europe.
Q:Can Consumables grow sequentially in the next quarter?
A:Management avoided being precise but stated they feel good about mid-single-digit growth for the year and next year, without committing to specific sequential growth.
Q:What is the traction for Duo in the Infusion Systems market, and are orders being taken for Solo?
A:Orders are being taken for Solo, and contracts are being signed. However, installs are still in the early stages, and management did not provide specific metrics but mentioned ongoing dialogue in the U.S. pump market.
Q:What is the outlook for tariff exposure in 2026?
A:Management reiterated previous comments, stating they are working on supply chain and manufacturing mitigations but avoided providing specific details, emphasizing they do not want the conversation to focus solely on tariffs.
Q:What happens after achieving the 45% gross margin target?
A:Management plans to focus on sustaining and improving technology value, changing the product mix, adding software products, and leveraging financial strategies like buybacks to drive earnings growth.
Q:What is the current pricing environment and contract renewals?
A:Management is focused on obtaining fair value for products, with a 1% overall price increase expected for the year. They acknowledged challenges in fixed-price contracts but are making efforts to improve pricing where possible.
Q:What is the opportunity for replacement cycles in Systems?
A:The replacement cycle for the installed base of Plum 360 and other devices like CADD and Medfusion is expected to start in earnest by mid to late next year, with benefits likely seen by the end of next year.
Q:What is the outlook for free cash flow?
A:Management sees free cash flow as a significant value driver, with potential improvements as remediation and restructuring expenses decrease. However, they cautioned against annualizing quarterly results due to variability.
Q:Is there any update on FDA warning letters?
A:There is no significant update. Management is focused on resolving the issues and obtaining new product approvals, with normal dialogue continuing with the FDA.
Q:What is the status of portfolio management within the Vital Care segment?
A:Management continues to evaluate strategic options for the segment but avoided committing to specific actions, citing the need for patience and the importance of not pursuing value-destructive moves.
Q:Review of Unclear Management Responses
A:Management avoided providing precise details on sequential growth for Consumables, specific metrics for Duo and Solo traction, detailed tariff mitigation strategies, and concrete plans for portfolio management within the Vital Care segment.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CADD
Consumables
ICR
LVP pump
Loan refinancing
Term Loan
afternoon ICU
balance comment
benefit Italy
benefit deconsolidation
census
comment digit
control
deconsolidation IV
deferral
development
digit rate
driver
exchange
goal improvement
hospital
income statement
installation
installs
item margin
margin goal
organic
payback liability
principal
program cash
pump base
rate percentage
rate share
reminder
safety
settlement
step
submission
syringe pump
tariff expense
thought
timing
ICUI Transcript
ICU Medical, Inc. (ICUI) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call presents a mixed picture. While there is strong performance in IV Systems and consistent guidance for EBITDA and EPS, the decline in Vital Care revenue and management's vague responses about certain issues could cause investor uncertainty. The company's focus on reducing debt and maintaining higher price points is positive, but the lack of immediate financial impact from new hardware and unresolved issues in Vital Care tempers optimism. The market cap suggests moderate volatility, leading to a neutral prediction for the stock price movement.
ICU Medical, Inc. (ICUI) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call summary indicates solid financial performance with increased EBITDA and EPS guidance, strong cash flow, and strategic debt management. Product development is on track, with no sales impact from pending clearances. Operational improvements are expected to enhance margins, and the company is optimistic about its backlog and product refresh cycle. Although tariffs impact costs, structural mitigation efforts are underway. The Q&A reveals a stable market environment and positive analyst sentiment, with no significant risks highlighted. Given the company's market cap, these factors suggest a positive stock price movement of 2% to 8%.
ICU Medical, Inc. (ICUI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
ICU Medical, Inc. (ICUI) Q3 2025 Earnings Call Transcript
Positive11-6
The company's Q3 results show strong financial performance with improved gross margins and EPS growth. The Consumables and IV Systems segments performed well, despite challenges in the Vital Care segment. Management's cautious optimism and strategic focus on growth areas like Consumables and Systems, coupled with efforts to mitigate tariff impacts, support a positive outlook. The market cap suggests moderate volatility, leading to a predicted positive stock price movement of 2% to 8%.
ICUI Slides
ICUI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
